Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023- EU5

Publisher Name :
Date: 31-Jan-2017
No. of pages: 60
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023-EU5" report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic stem cell transplantations (HSCTs) and Graft Versus Host Disease (GVHD) based upon the sub-types of GVHD along with the type of donor involved in the HSCTs, for the forecast period (2013-2023).

GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). DelveInsight forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to DelveInsight's estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.71% from 2013-2023 and reach up to 30,328 cases in the year 2023.

The incident rate of GVHD in unrelated donor (URD) is much higher in comparison to the sibling donors (SD), irrespective of the sub-types i.e., acute GVHD (aGVHD) or chronic GVHD (cGVHD). As per DelveInsight forecasts, the diagnosed incidence cases of aGVHD in sibling donors and aGVHD in unrelated donors, shall increase at a CAGR of 3.96% and 4.05%, respectively, from 2013-2023. In case of cGVHD, the number of diagnosed incident population cGVHD in sibling donors and cGVHD in unrelated donors is expected to accentuate at a CAGR of 4.05% and 4.04%, respectively, by the end of the year 2023.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Scope

- Report covers the disease overview including pathophysiology, symptoms, diagnosis and disease management.

- It focuses on the risk factors and the historical trends of the diagnosed incident cases of allogeneic Hematopoietic Stem Cell Transplants (HSCTs) ( which also includes the cases of first transplants along with the total transplants)

- The Report also covers the detailed historical and forecasted number of diagnosed incident cases of acute GVHD and chronic GVHD, segmented by the type of donors (Sibling donors and unrelated donors) for the EU5 countries(Germany, France, Italy, Spain and United Kingdom) from 2013-2023.

Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023- EU5

Table of Contents

Graft Versus Host Disease (GVHD)
Disease Definition
Disease Types
Acute GvHD
Chronic GvHD
Grades of GvHD
Pathophysiology
Risk Factors for GVHD
Diagnosis
Epidemiology and Patient Population
Key Points
Germany
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany (2013-2023)
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
France
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France (2013-2023)
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Spain
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain (2013-2023)
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Italy
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy (2013-2023)
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
United Kingdom
Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom (2013-2023)
Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Assumptions and Rationale
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight


List of Tables

Table 1: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany (2013-2023)
Table 2: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Table 3: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Table 4: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France (2013-2023)
Table 5: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Table 6: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Table 7: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain (2013-2023)
Table 8: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Table 9: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Table 10: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy (2013-2023)
Table 11: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Table 12: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Table 13: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom (2013-2023)
Table 14: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Table 15: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)


List of Figures

Figure 1: Pathophysiology of GvHD
Figure 2: Risk Factors for GvHD
Figure 3: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany (2013-2023)
Figure 4: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Figure 5: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2013-2023)
Figure 6: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France (2013-2023)
Figure 7: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Figure 8: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2013-2023)
Figure 9: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain (2013-2023)
Figure 10: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Figure 11: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2013-2023)
Figure 12: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy (2013-2023)
Figure 13: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Figure 14: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2013-2023)
Figure 15: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom (2013-2023)
Figure 15: Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
Figure 16: Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2013-2023)
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Asia-Pacific Minocycline Hydrochloride Market by Manufacturers, Regions, Type and Application, Forecast to 2022
    Published: 27-Apr-2017        Price: US 4480 Onwards        Pages: 123
    Minocycline Hydrochloride, also called minocycline HCL, is a broad-spectrum tetracycline antibiotic, and has a broader spectrum than the other members of the group. It is a bacteriostatic antibiotic, classified as a long-acting type. As a result of its long half-life it generally has serum levels 2-4 times that of the simple water-soluble tetracyclines. The CAS?Number?is 13614-98-7.Scope of the Report:This report focuses on the Minocycline Hydrochloride in Asia-Pacific mar......
  • Global Hyoscine-N-Butyl Bromide Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 26-Apr-2017        Price: US 3480 Onwards        Pages: 118
    Hyoscine-N-Butyl Bromideis obtained from a species of the plant genus Duboisia. It is mainly classified as an antispasmodic, which means that it is a drug used to suppress of muscle spasms, or involuntary contractions.Scope of the Report:This report focuses on the Hyoscine-N-Butyl Bromide in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and......
  • Global Medical Grade Hydrogel Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 26-Apr-2017        Price: US 3480 Onwards        Pages: 117
    Hydrogel is gel-like or colloidal substances made of water and solids. Hydrogels are highly absorbent (they can contain over 90% water) natural or synthetic polymeric networks. It is widely used in medical fields, industrial fields, consumer goods etc.Scope of the Report:This report focuses on the Medical Grade Hydrogel in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on ......
  • North America Procalcitonin (CAS 56645-65-9) Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 26-Apr-2017        Price: US 4480 Onwards        Pages: 116
    Procalcitonin (PCT) is a 116 amino acid residue protein with a molecular weight of approximately 13kDa. Procalcitonin is a peptide hormone mainly produced by the C cells of the thyroid and certain endocrine cells of the lung. Under normal expression conditions, procalcitonin is immediately cleaved into three specific fragments, an N terminal residue, calcitonin and katacalcin.Scope of the Report:This report focuses on the Procalcitonin (CAS 56645-65-9) in North America mar......
  • Global Dyslipidemia Drugs Market Professional Survey Report 2017
    Published: 26-Apr-2017        Price: US 3500 Onwards        Pages: 113
    This report studies Dyslipidemia Drugs in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - AstraZeneca - Merck - Pfizer - Bayer - Abbott Laboratories......
  • Global Measles Vaccine Market Research Report 2017
    Published: 26-Apr-2017        Price: US 2900 Onwards        Pages: 116
    In this report, the global Measles Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Measles Vaccine in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Jap......
  • Global Oral Rotavirus Vaccine Market Research Report 2017
    Published: 26-Apr-2017        Price: US 2900 Onwards        Pages: 102
    In this report, the global Oral Rotavirus Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Oral Rotavirus Vaccine in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - Chin......
  • EMEA (Europe, Middle East and Africa) Anti-Infective Drugs Market Report 2017
    Published: 26-Apr-2017        Price: US 4000 Onwards        Pages: 110
    In this report, the EMEA Anti-Infective Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K MT), revenue (Million USD), market share and growth rate of Anti-Infective Drugs for these regions, from 2012 to 2022 (forecast) - Europe: Germany, France, UK, Russia, Italy and Benelux;......
  • Global Poliomyelitis Vaccine Market Research Report 2017
    Published: 26-Apr-2017        Price: US 2900 Onwards        Pages: 101
    In this report, the global Poliomyelitis Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Poliomyelitis Vaccine in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs